{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:44Z","timestamp":1740106904276,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00277-021-04469-0","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T21:02:30Z","timestamp":1614718950000},"page":"1345-1347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse\/refractory mantle cell lymphoma"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4686-9273","authenticated-orcid":false,"given":"Louise","family":"Roulin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"issue":"11","key":"4469_CR1","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","volume":"34","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Seymour JF, Wang ML (2016) Mantle cell lymphoma. J Clin Oncol 34(11):1256\u20131269","journal-title":"J Clin Oncol"},{"issue":"16","key":"4469_CR2","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks K (2018) Update on mantle cell lymphoma. Blood 132(16):1647\u20131656","journal-title":"Blood"},{"issue":"5","key":"4469_CR3","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","volume":"126","author":"M-H Delfau-Larue","year":"2015","unstructured":"Delfau-Larue M-H, Klapper W, Berger F, Jardin F, Briere J, Salles G, Casasnovas O, Feugier P, Haioun C, Ribrag V, Thieblemont C, Unterhalt M, Dreyling M, Macintyre E, Pott C, Hermine O, Hoster E, European Mantle Cell Lymphoma Network (2015) High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood 126(5):604\u2013611","journal-title":"Blood"},{"issue":"13","key":"4469_CR4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW (2018) Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med 378(13):1211\u20131223","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"4469_CR5","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1182\/blood-2019-128299","volume":"134","author":"C Jiang","year":"2019","unstructured":"Jiang C, Zhang R, Zhang S et al (2019) Targeting PI3K and PLK1 to overcome ibrutinib-venetoclax resistance in mantle cell lymphoma. Blood 134(Supplement_1):4062\u20134062","journal-title":"Blood"},{"issue":"Supplement 1","key":"4469_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2020-140871","volume":"136","author":"VC Jiang","year":"2020","unstructured":"Jiang VC, Lian J, Huang S et al (2020) Oncogenic MALT1 promotes cell survival and mediates ibrutinib resistance and ibrutinib-venetoclax resistance in mantle cell lymphoma. Blood 136(Supplement 1):18\u201318","journal-title":"Blood"},{"issue":"Supplement 1","key":"4469_CR7","first-page":"33","volume":"136","author":"VC Jiang","year":"2020","unstructured":"Jiang VC, Zhang S, Lian J et al (2020) Single cell transcriptomic evolution and resistance mechanisms of BTK and BCL-2 inhibition in mantle cell lymphoma. Blood 136(Supplement 1):33\u201334","journal-title":"Blood"},{"issue":"Supplement 1","key":"4469_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-140849","volume":"136","author":"AA Jordan","year":"2020","unstructured":"Jordan AA, McIntosh J, Liu Y et al (2020) Targeting antibody checkpoint Fcgriib using monoclonal antibody BI-1206 to overcome therapeutic resistance in mantle cell lymphoma. Blood 136(Supplement 1):35","journal-title":"Blood"},{"issue":"11","key":"4469_CR9","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1080\/10428194.2019.1602268","volume":"60","author":"PJ Hampel","year":"2019","unstructured":"Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA (2019) Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leukemia Lymphoma 60(11):2712\u20132719","journal-title":"Leukemia Lymphoma"},{"issue":"15_suppl","key":"4469_CR10","doi-asserted-by":"publisher","first-page":"8028","DOI":"10.1200\/JCO.2020.38.15_suppl.8028","volume":"38","author":"AR Mato","year":"2020","unstructured":"Mato AR, Sharman JP, Biondo J et al (2020) Impact of premature venetoclax (Ven) discontinuation\/interruption on outcomes in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results. JCO 38(15_suppl):8028","journal-title":"JCO"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04469-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04469-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04469-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T04:04:41Z","timestamp":1618286681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04469-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["4469"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04469-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"22 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Corinne Haioun received honoraria from Roche, Janssen-Cilag, Gilead, Takeda, Miltenyi, and Servier. Francois Lemonnier and Louise Roulin declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}